STOCK TITAN

Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Marinus Pharmaceuticals (Nasdaq: MRNS) has announced the agenda and speakers for its Investor & Analyst Day on September 20, 2024. The event will focus on the development and commercial launch preparations for ZTALMY® (ganaxolone) in tuberous sclerosis complex (TSC). Key highlights include:

1. Updated baseline patient demographics from the Phase 3 TrustTSC trial
2. Market opportunity in TSC
3. New open label extension data from the Phase 2 TSC clinical trial
4. Plans to expand clinical pipeline in other neurodevelopmental epilepsies
5. Presentations from Marinus leadership and key opinion leaders

The TrustTSC trial topline data is expected in Q4 2024. The event will be accessible via live video webcast for virtual participants.

Marinus Pharmaceuticals (Nasdaq: MRNS) ha annunciato l'agenda e i relatori per il suo Investor & Analyst Day del 20 settembre 2024. L'evento si concentrerà sui preparativi per lo sviluppo e il lancio commerciale di ZTALMY® (ganaxolone) nel complesso di scleroisi tuberosa (TSC). I punti salienti includono:

1. Aggiornamenti sui dati demografici dei pazienti di base provenienti dal trial di fase 3 TrustTSC
2. Opportunità di mercato nel TSC
3. Nuovi dati di estensione a etichetta aperta dal trial clinico di fase 2 TSC
4. Piani per ampliare il pipeline clinico in altre epilessie neuroevolutive
5. Presentazioni da parte della leadership di Marinus e leader di opinione chiave

I dati principali del trial TrustTSC sono attesi per il Q4 2024. L'evento sarà accessibile tramite webcasting video dal vivo per i partecipanti virtuali.

Marinus Pharmaceuticals (Nasdaq: MRNS) ha anunciado la agenda y los ponentes para su Investor & Analyst Day el 20 de septiembre de 2024. El evento se centrará en los preparativos para el desarrollo y lanzamiento comercial de ZTALMY® (ganaxolone) en el complexo de esclerosis tuberosa (TSC). Los aspectos destacados incluyen:

1. Datos demográficos actualizados de la línea base de los pacientes del ensayo de fase 3 TrustTSC
2. Oportunidades de mercado en TSC
3. Nuevos datos de extensión abierta del ensayo clínico de fase 2 TSC
4. Planes para expandir la cartera clínica en otras epilepsias neurodesarrolladas
5. Presentaciones de la dirección de Marinus y líderes de opinión clave

Los datos principales del ensayo TrustTSC se esperan para el Q4 2024. El evento será accesible a través de una transmisión en vivo por video para participantes virtuales.

Marinus Pharmaceuticals (Nasdaq: MRNS)는 2024년 9월 20일 투자자 및 분석가의 날 일정과 연사를 발표했습니다. 이번 행사에서는 ZTALMY® (ganaxolone)토버러스 경화증 복합체 (TSC)에서의 개발 및 상업적 출시 준비에 초점을 맞출 것입니다. 주요 하이라이트는 다음과 같습니다:

1. 3상 TrustTSC 시험에서의 최신 기본 환자 인구 통계
2. TSC에서의 시장 기회
3. 2상 TSC 임상 시험의 새로운 개방형 확장 데이터
4. 다른 신경 발달 간질에서의 임상 파이프라인 확장 계획
5. Marinus 리더십 및 주요 의견 리더의 발표

TrustTSC 시험의 주요 데이터는 2024년 4분기에 발표될 예정입니다. 이 행사는 가상 참가자를 위한 라이브 비디오 웹캐스트를 통해 접근이 가능합니다.

Marinus Pharmaceuticals (Nasdaq: MRNS) a annoncé l'agenda et les intervenants pour son Investor & Analyst Day du 20 septembre 2024. L'événement se concentrera sur le développement et les préparatifs de lancement commercial de ZTALMY® (ganaxolone) dans le complexe de sclérose tubéreuse (TSC). Les points clés incluent :

1. Données démographiques de base mises à jour des patients de l'
2. Opportunités de marché dans le TSC
3. Nouvelles données d'extension ouverte de l'
4. Plans pour élargir le pipeline clinique dans d'autres épilepsies neurodéveloppementales
5. Présentations de la direction de Marinus et d'opinions clés

Les données principales de l'essai TrustTSC sont attendues pour le T4 2024. L'événement sera accessible via un webinaire vidéo en direct pour les participants virtuels.

Marinus Pharmaceuticals (Nasdaq: MRNS) hat die Agenda und die Redner für seinen Investor & Analyst Day am 20. September 2024 bekannt gegeben. Die Veranstaltung wird sich auf die Entwicklung und die kommerziellen Vorbereitungen für ZTALMY® (ganaxolone) bei tuberöser Sklerose (TSC) konzentrieren. Zu den wichtigsten Highlights gehören:

1. Aktualisierte Basisdaten der Patienten demografie aus der Phase 3 TrustTSC Studie
2. Marktchancen in TSC
3. Neue offene Verlängerungsdaten aus der Phase 2 TSC klinischen Studie
4. Pläne zur Erweiterung der klinischen Pipeline bei anderen neurodevelopmentalen Epilepsien
5. Präsentationen von Marinus-Führungskräften und wichtigen Meinungsbildnern

Die wichtigsten Daten der TrustTSC Studie werden im Q4 2024 erwartet. Die Veranstaltung wird für virtuelle Teilnehmer über einen Live-Video-Webcast zugänglich sein.

Positive
  • Upcoming Investor & Analyst Day to showcase ZTALMY® development and commercial launch preparations
  • New open label extension data from Phase 2 TSC clinical trial to be presented
  • Plans to expand clinical pipeline in other neurodevelopmental epilepsies
  • Phase 3 TrustTSC trial topline data expected in Q4 2024
Negative
  • None.

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced agenda topics and speakers for its upcoming Investor & Analyst Day on Friday, September 20 from 9:00 a.m. to 12:00 p.m. ET in New York.

The event will feature presentations from Marinus’ leadership and key opinion leaders (KOLs) with a focus on the development program and commercial launch preparations for ZTALMY® (ganaxolone) oral suspension CV in tuberous sclerosis complex (TSC). Marinus’ leadership will provide updated baseline patient demographics and characteristics from the Phase 3 TrustTSC trial and discuss the market opportunity in TSC. KOLs will share their clinical experiences with TSC, present new open label extension data from Marinus’ Phase 2 TSC clinical trial, and provide an overview on the burden of illness, current treatment landscape, and limitations. In addition, Marinus’ leadership will highlight how the Company is planning to expand its clinical pipeline with development programs in other neurodevelopmental epilepsies, pending the results of the TrustTSC trial which is expected to readout topline data in the first half of the fourth quarter of 2024.

Marinus Speakers:

  • Scott Braunstein, M.D., Chairman of the Board and Chief Executive Officer
  • Steven E. Pfanstiel, Chief Financial Officer and Chief Operating Officer
  • Joseph Hulihan, M.D., Chief Medical Officer
  • Christy Shafer, Chief Commercial Officer
  • Alex Aimetti, Ph.D., Chief Scientific Officer
  • Sonya Weigle, Chief People and Investor Relations Officer
  • Lisa Lejuwaan, Senior Vice President and Business Unit Lead, Rare Genetic Epilepsy

KOL Speakers:

  • Dr. Mary Kay Koenig, M.D., Director of the Center for Treatment of Pediatric Neurodegenerative Disease (CTPND), Director of Research for the Division of Child and Adolescent Neurology at the University of Texas McGovern Medical School
  • Dr. Rajsekar R. Rajaraman, M.D., M.S., Director of the UCLA Tuberous Sclerosis Center of Excellence and the UCLA CDKL5 Center of Excellence, Associate Professor in Pediatric Neurology at UCLA Mattel Children's Hospital

In-person attendance is open to invited research analysts and institutional investors. All others are invited to watch the live video webcast. Live questions will be taken by in-person guests, and virtual participants may submit questions through the webcast platform.

To register for the video webcast, please visit the Investor Relations section of the Company's website at https://ir.marinuspharma.com/events-and-presentations/. A replay of the webcast will be archived on the Investor Relations section of the Company's website following the event.

Featured KOL Speaker Biographies:
Dr. Mary Kay Koenig serves as the Director of the CTPND and Director of Research for the Division of Child & Adolescent Neurology at the University of Texas McGovern Medical School. Dr. Koenig attended the University of Texas in Austin where she received a Bachelor of Arts in Biochemistry. Following undergraduate school, Dr. Koenig received a Master's of Science in Microbiology at Southwest Texas State University followed by her Medical Doctorate at St. George’s School of Medicine. After medical school, Dr. Koenig completed a pediatrics residency at the University of Texas Medical Branch in Galveston and a fellowship in Child and Adolescent Neurology at The University of Texas Medical School. Upon completion of her fellowship, she joined the faculty and is now a tenured professor. She has served as the director for the UT Mitochondrial Center of Excellence since 2007, the co-Director for the UT Memorial Hermann Tuberous Sclerosis Clinic since 2007, and the Leigh Syndrome clinic director since 2013. Dr. Koenig strives to provide excellent clinic care and advance research for children afflicted with genetic neurodegenerative disease. She also works to mentor and educate junior faculty, fellows, residents, and medical students in the art of medicine and clinical research.

Dr. Rajsekar "Raj" Rajaraman is an Associate Professor in Pediatric Neurology at the UCLA Mattel Children's Hospital. He completed his Pediatric Neurology residency, Clinical Neurophysiology fellowship, and Epilepsy fellowship training at UCLA. A native of New Jersey, Dr. Rajaraman completed his pediatrics residency at the Unterberg Children's Hospital at Monmouth Medical Center in New Jersey. During his pediatric residency, his exposure to seizures and the effects that epilepsy has on the patient and family led to him pursuing a career in pediatric epileptology at UCLA. Currently, his clinical and research interests involve all aspects of infantile spasms, as well as its effects in Tuberous Sclerosis and CDKL5 Deficiency Disorder. Dr. Rajaraman is currently the Director of the UCLA Tuberous Sclerosis Center of Excellence as well as the UCLA CDKL5 Center of Excellence. He is the primary investigator of over a dozen pharmaceutical and investigator driven clinical trials and studies. He has presented research at multiple conferences, including the American Academy of Neurology, Child Neurology Society, and the American Epilepsy Society, receiving achievements including the national 2014 American Epilepsy Society Young Investigator Award. Dr. Rajaraman has multiple publications on rare developmental epileptic encephalopathies (DEE). In addition to his clinical and research interests, Dr. Rajaraman is an active member of the American Academy of Neurology (AAN) and American Epilepsy Society (AES). He volunteers for the Epilepsy Foundation of Greater Los Angeles, including helping at their annual Walk to End Epilepsy at the Rose Bowl, as well as the Epilepsy Awareness Day at Disneyland.

About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s product, ZTALMY ® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U.S. in 2022. For more information, please visit www.marinuspharma.com and follow us on Facebook, LinkedIn and X.

Investors

Sonya Weigle

Chief People and Investor Relations Officer

Marinus Pharmaceuticals, Inc.

sweigle@marinuspharma.com

Media

Molly Cameron

Director, Corporate Communications & Investor Relations

Marinus Pharmaceuticals, Inc.

mcameron@marinuspharma.com

Source: Marinus Pharmaceuticals

FAQ

When is Marinus Pharmaceuticals (MRNS) hosting its Investor & Analyst Day?

Marinus Pharmaceuticals (MRNS) is hosting its Investor & Analyst Day on Friday, September 20, 2024, from 9:00 a.m. to 12:00 p.m. ET in New York.

What is the main focus of Marinus Pharmaceuticals' (MRNS) Investor & Analyst Day?

The main focus is on the development program and commercial launch preparations for ZTALMY® (ganaxolone) oral suspension CV in tuberous sclerosis complex (TSC).

When are the topline data results expected for Marinus Pharmaceuticals' (MRNS) TrustTSC trial?

The topline data results for Marinus Pharmaceuticals' (MRNS) TrustTSC trial are expected in the first half of the fourth quarter of 2024.

What new data will be presented at Marinus Pharmaceuticals' (MRNS) Investor & Analyst Day?

New open label extension data from Marinus Pharmaceuticals' (MRNS) Phase 2 TSC clinical trial will be presented at the Investor & Analyst Day.

Marinus Pharmaceuticals, Inc

NASDAQ:MRNS

MRNS Rankings

MRNS Latest News

MRNS Stock Data

16.85M
49.03M
10.94%
83.04%
10.28%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
RADNOR